Therapy Detail

Therapy Name MRK-003 + Paclitaxel
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MRK-003 Gamma secretase inhibitor 12 MRK-003 is a gamma-secretase inhibitor which inhibits Notch3 signaling and induces apoptosis in cancer cells (PMID: 17804716).
Paclitaxel Taxol 7-Epipaclitaxel Antimicrotubule Agent 11 BCL2 Family Inhibitor 6 Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
NOTCH1 wild-type triple-receptor negative breast cancer no benefit MRK-003 + Paclitaxel Preclinical Actionable In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330). 25104330
NOTCH1 rearrange triple-receptor negative breast cancer sensitive MRK-003 + Paclitaxel Preclinical Actionable In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330). 25104330
Clinical Trial Phase Therapies Title Recruitment Status